OCS

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

18.500

Open

18.240

VWAP

18.30

Vol

11.84K

Mkt Cap

929.28M

Low

17.780

Amount

216.59K

EV/EBITDA(TTM)

Total Shares

46.44M

923.47M

EV/OCF(TTM)

P/S(TTM)

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

151.67K

-38.09%

151.67K

-29.78%

150.00K

+4900%

Estimates Revision

The market is revising Downward the revenue expectations for Oculis Holding AG (OCS) for FY2025, with the revenue forecasts being adjusted by -90.37% over the past three months. During the same period, the stock price has changed by -15.96%.

Revenue Estimates for FY2025

Revise Downward

-90.37%

In Past 3 Month

Stock Price

Go Down

-15.96%

In Past 3 Month

5 Analyst Rating

96.08% Upside

Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 35.00 USD with a low forecast of 32.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

96.08% Upside

Current: 17.850

Low

32.00

Averages

35.00

High

41.00

96.08% Upside

Current: 17.850

Low

32.00

Averages

35.00

High

41.00

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$28 → $33

2025-05-09

Reason

Chardan Capital

Daniil Gataulin

Price Target

$28 → $33

2025-05-09

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$29 → $32

2025-04-17

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$29 → $32

2025-04-17

Maintains

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$28

2025-04-17

Reason

Chardan Capital

Daniil Gataulin

Price Target

$28

2025-04-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$30 → $29

2025-03-13

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$30 → $29

2025-03-13

Maintains

Strong Buy

Reason

Baird

Colleen Kusy

Buy

Maintains

$37 → $41

2025-03-13

Reason

Baird

Colleen Kusy

Price Target

$37 → $41

2025-03-13

Maintains

Buy

Reason

Baird analyst Colleen Kusy raised the firm's price target on Oculis to $41 from $37 and keeps an Outperform rating on the shares. The firm updated it model following Q4 results which showed programs for DME, AON, and Dry Eye are progressing.

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$28

2025-03-13

Reason

Chardan Capital

Daniil Gataulin

Price Target

$28

2025-03-13

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Oculis Holding AG (OCS.O) is -8.66, compared to its 5-year average forward P/E of -4.83. For a more detailed relative valuation and DCF analysis to assess Oculis Holding AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.83

Current PE

-8.66

Overvalued PE

-1.46

Undervalued PE

-8.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.21

Current EV/EBITDA

-7.46

Overvalued EV/EBITDA

-1.12

Undervalued EV/EBITDA

-9.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

405.47

Current PS

1222.28

Overvalued PS

747.47

Undervalued PS

63.46